Ablynx

Beleggen in aandelen beurs Brussel, BEL 20, lokale fondsen, etc.
DeCJ
Forum gebruiker
Forum gebruiker
Berichten: 108
Lid geworden op: 14 Mar 2012 11:50
Contact:

Ablynx

Berichtdoor DeCJ » 19 Mar 2012 15:14

Is er nieuws? Koersstijging van meer dan 5 % vandaag..
frikandel75 liked last!


Minder reclame en meer functies?
Registreer binnen 1 minuut


Minder reclame en meer functies?
Registreer binnen 1 minuut

rouches
Forum actieveling
Forum actieveling
Berichten: 561
Lid geworden op: 02 Jan 2012 23:25
Contact:

Re: ABLYNX

Berichtdoor rouches » 19 Mar 2012 15:42

Mijn gemiddelde is 6.55 dus nog een hele weg te gaan. Misschien hebben ze al een nieuwe partner gevonden... :roll:
OPXA 2.50, ELTP 0.23, BTX 3.00, TIG 0.71, GALE 0.60, SMARTPHOTO 0.40

beursbink
Forum gebruiker
Forum gebruiker
Berichten: 116
Lid geworden op: 03 Jan 2012 22:37
Contact:

Re: ABLYNX

Berichtdoor beursbink » 19 Mar 2012 17:28

DeCJ schreef:Is er nieuws? Koersstijging van meer dan 5 % vandaag..


met dank aan hugbu1 op dat andere forum......
http://www.edisoninvestmentresearch.co. ... Update.pdf
misschien zit dat er voor een stuk tussen?

DeCJ
Forum gebruiker
Forum gebruiker
Berichten: 108
Lid geworden op: 14 Mar 2012 11:50
Contact:

Re: ABLYNX

Berichtdoor DeCJ » 20 Mar 2012 12:47

Ah ja, dat zal het zijn! :D

rouches
Forum actieveling
Forum actieveling
Berichten: 561
Lid geworden op: 02 Jan 2012 23:25
Contact:

Re: ABLYNX

Berichtdoor rouches » 20 Mar 2012 19:25

OPXA 2.50, ELTP 0.23, BTX 3.00, TIG 0.71, GALE 0.60, SMARTPHOTO 0.40

beursbink
Forum gebruiker
Forum gebruiker
Berichten: 116
Lid geworden op: 03 Jan 2012 22:37
Contact:

Re: ABLYNX

Berichtdoor beursbink » 21 Mar 2012 10:07

iedereen weer tevreden nu meen ik :P

wiedes
Forum actieveling
Forum actieveling
Berichten: 471
Lid geworden op: 06 Apr 2012 23:50
Contact:

Doorbraak voor ABLYNX?

Berichtdoor wiedes » 08 Apr 2012 09:25

Is onderstaande significant of opgewarmde marketingkost? :?:
GHENT, Belgium, 4 April 2012 - Ablynx [Euronext Brussels: ABLX] today noted that a paper on a novel tetrameric Nanobody agonist (TAS266) targeting Death Receptor 5 (DR5), a key receptor target on cancer cells across a number of tumour types, was presented at the American Association for Cancer Research Annual Meeting in Chicago, USA, on 3 April 2012 by Novartis. The ability of TAS266 to efficiently ‘cross-link’ DR5 receptor targets, apparently not achievable with conventional monoclonal antibodies, results in the controlled death of cancer cells.
The paper was presented by Dr Heather Huet from Novartis and the authors included three scientists from Ablynx.
The abstract summarizes the results of the pre-clinical in vitro and in vivo studies of a tetravalent anti-DR5 Nanobody in an oncology setting. TAS266 was shown to elicit sustained tumour regressions in multiple tumour xenograft models, including a patient-derived primary pancreatic tumour model that is insensitive to a conventional anti-DR5 agonist antibody. Also, compared to some of the other therapeutic agonists against DR5 that have been developed and that have been clinically evaluated, TAS266 proved to be up to 1000-fold more potent in tumour cell death assays.
In view of this, the authors of the abstract conclude that “TAS266 has the potential for superior clinical activity in settings insensitive to the conventional therapeutic approaches to DR5.”
The abstract further states that “first-in-man trials for TAS266 are expected to begin in 2012.”
Link to the presentation abstract: “TAS266, a novel tetrameric Nanobody agonist targeting death receptor 5 (DR5), elicits superior anti-tumour efficacy than conventional DR5-targeted approaches.”
Commenting on today’s announcement, Dr Edwin Moses, Chairman and CEO of Ablynx, said:
“Being present on cancer cells across a broad range of tumour types, DR5 has been the target of numerous conventional antibody approaches, but none have apparently been successful so far, possibly because of the need for secondary ‘cross-linking’ to achieve the required activity. The ability to produce tetravalent Nanobodies appears to allow more efficient ‘cross-linking’ (in the tumour micro-environment) and so potentially opens up a new pathway for the treatment of certain cancers.”

wiedes
Forum actieveling
Forum actieveling
Berichten: 471
Lid geworden op: 06 Apr 2012 23:50
Contact:

Re: ABLYNX

Berichtdoor wiedes » 10 Apr 2012 18:38

Volgt hier niemand nog Ablynx?

Fooz
Forum verkenner
Forum verkenner
Berichten: 50
Lid geworden op: 10 Jan 2012 18:39
Contact:

Re: ABLYNX

Berichtdoor Fooz » 10 Apr 2012 18:48

Ik volg het een beetje, maar momenteel precies nie veel aan het firmament... geen nieuws is goed nieuws hé.

Maarten
Forum actieveling
Forum actieveling
Berichten: 389
Lid geworden op: 05 Jan 2012 10:36
Contact:

Re: Doorbraak voor ABLYNX?

Berichtdoor Maarten » 12 Apr 2012 11:22

wiedes schreef:Is onderstaande significant of opgewarmde marketingkost? :?:
GHENT, Belgium, 4 April 2012 - Ablynx [Euronext Brussels: ABLX] today noted that a paper on a novel tetrameric Nanobody agonist (TAS266) targeting Death Receptor 5 (DR5), a key receptor target on cancer cells across a number of tumour types, was presented at the American Association for Cancer Research Annual Meeting in Chicago, USA, on 3 April 2012 by Novartis. The ability of TAS266 to efficiently ‘cross-link’ DR5 receptor targets, apparently not achievable with conventional monoclonal antibodies, results in the controlled death of cancer cells.
The paper was presented by Dr Heather Huet from Novartis and the authors included three scientists from Ablynx.
The abstract summarizes the results of the pre-clinical in vitro and in vivo studies of a tetravalent anti-DR5 Nanobody in an oncology setting. TAS266 was shown to elicit sustained tumour regressions in multiple tumour xenograft models, including a patient-derived primary pancreatic tumour model that is insensitive to a conventional anti-DR5 agonist antibody. Also, compared to some of the other therapeutic agonists against DR5 that have been developed and that have been clinically evaluated, TAS266 proved to be up to 1000-fold more potent in tumour cell death assays.
In view of this, the authors of the abstract conclude that “TAS266 has the potential for superior clinical activity in settings insensitive to the conventional therapeutic approaches to DR5.”
The abstract further states that “first-in-man trials for TAS266 are expected to begin in 2012.”
Link to the presentation abstract: “TAS266, a novel tetrameric Nanobody agonist targeting death receptor 5 (DR5), elicits superior anti-tumour efficacy than conventional DR5-targeted approaches.”
Commenting on today’s announcement, Dr Edwin Moses, Chairman and CEO of Ablynx, said:
“Being present on cancer cells across a broad range of tumour types, DR5 has been the target of numerous conventional antibody approaches, but none have apparently been successful so far, possibly because of the need for secondary ‘cross-linking’ to achieve the required activity. The ability to produce tetravalent Nanobodies appears to allow more efficient ‘cross-linking’ (in the tumour micro-environment) and so potentially opens up a new pathway for the treatment of certain cancers.”

Is mooi, maar TAS266 moet nog aan phase I beginnen. Nog een long way to go dus, maar klinkt wel al veelbelovend.
Ablx,Barco,Bekaert,CFE,Bois Sauv,CMB,Exmar,GIMV,Global Graph,MDX,Nyrstar,Picanol,QuestfG,RealDolmen,Recticel,Resilux,SAPEC,SBM,Softimat,Thrombo,Tubize